logo-loader

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

Published: 00:51 27 Apr 2018 AEST

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED).

The study will recruit approximately 1,000 patients with mild, moderate and severe ED and compare the efficacy of 0.2%, 0.4% and 0.6% GTN doses of MED2002 against that of the placebo.

Conviviality puts brakes on dividend as hangover worsens

AIM Journal's Andrew Hore speaks to Proactive Investors about Conviviality (LON:CVL) drowning in worries and looks ahead to the good news to come for erectile dysfunction treatment manufacturer Futura Medical (LON:FUM). Hore also discusses the spectrum of telecommunications activities...

on 17/3/18
OSZAR »